Oxford Biomedica Logo
Scientist microscope

Press releases 2006

Date Headline
21/12/06 Oxford BioMedica and Sigma-Aldrich Issue Joint Licence for LentiVector® Technology to GlaxoSmithKline
19/12/06 Oxford BioMedica Expands Licensing Agreement for LentiVector® Technology with Major Pharmaceutical Company
08/12/06 Oxford BioMedica's Trovax® Receives Positive Recommendation for Orphan Drug Designation in Renal Cancer from EMEA
13/11/06 Oxford BioMedica Presents Encouraging Preclinical Efficacy Data with ProSavin® in Parkinson's Disease
09/11/06 Oxford BioMedica Reports Further Encouraging Phase II Results with Trovax® in Renal and Prostate Cancer
07/11/06 Oxford BioMedica Commences Phase III Trial of TroVax®
06/10/06 Oxford BioMedica Presents Encouraging Immunological Data From Six Phase Il Trials of TroVax® in Various Cancer
02/10/06 Oxford BioMedica Expands Its Ocular Programme Through Collaboration and Investment Led by the Foundation Fighting Blindness
05/09/06 Oxford BioMedica Plc Interim Results for the six months ended 30 June 2006
05/09/06 Southwest Oncology Group to Start Phase II Trial of Oxford BioMedica's TroVax in Breast Cancer
21/08/06 Leading US clinician to present on Oxford BioMedica's TroVax® at cancer conference
02/08/06 Oxford BioMedica Notice of Interim Results for the Six Months Ended 30 June 2006
31/07/06 Update and Clarification on TroVax
26/06/06 Oxford BioMedica Receives Notice of Allowance for Key US Patent Covering Parkinson's Disease Product, Prosavin®
21/06/06 Oxford BioMedica to Present at Piper Jaffray Health Care Conference
14/06/06 Oxford BioMedica and Partner Sigma-Aldrich Pursue Protection of RNAi-Related IP Against Open Biosystems
07/06/06 Oxford BioMedica Reports New Encouraging Phase II Results with TroVax® and Progress in the Development Plan
23/05/06 Oxford BioMedica Commences Phase II Trial of TroVax® in Prostate Cancer
12/05/06 Oxford BioMedica Secures Agreement with FDA on Special Protocol Assessment for Phase III Trial of TroVax in Renal Cancer
04/05/06 Oxford BioMedica Annual General Meeting 2006
02/05/06 Oxford BioMedica Reports Encouraging Preclinical Data with RetinoStat® in Retinopathy and Demonstrates the Potential of Lentivector® in other Ocular Diseases
30/03/06 Oxford BioMedica and its Collaborators to Report TroVax® Clinical Trial Results at American Society of Clinical Oncology Meeting
14/03/06 Oxford BioMedica plc Preliminary Results for the Year Ended 31 December 2005
10/03/06 Oxford BioMedica Licenses Its Gene Delivery Technology To VIRxSYS Corporation
23/02/06 Oxford BioMedica: Notice Of FY2005 Preliminary Results
03/02/06 Oxford BioMedica Announces Board Appointment
18/01/06 Oxford BioMedica and Viragen Report Avian Transgenic Breakthrough